Mon, 26 August 2013
ASCO Lung Cancer Highlights, Part 10: Strategies After Resistance to Crizotinib in ALK-Positive Advanced NSCLC (audio)
Dr. Edward Garon, David Geffen School of Medicine at UCLA, describes the exciting developments with LDK-378 and potentially other second generation ALK inhibitors for crizotinib-resistant ALK-positive advanced NSCLC.
Direct download: GRACEcast-169_Lung-Audio_ASCO_2013_2nd_Generation_ALK_Inhibitors.mp3
Category:Lung-Cancer-Audio -- posted at: 4:54pm PDT